BioNTech plans to start deliveries of two suitable vaccines for the Omicron variant of the coronavirus from October, the German laboratory said on Monday during the presentation of its results, Reuters reports.
If the demand for vaccines decreases in the world, because most people in Western countries have already received three or four doses, the withdrawal campaigns planned for the fall should stimulate demand again. BioNTech says it’s ready, with two proper shots.
Objective BA.1, BA.4 and BA.5
BioNTech and Pfizer submitted one of the combination vaccines, which targets the BA.1 subvariant, to the European Medicines Agency last month, with delivery pending approval. The other, which targets the BA.4 and BA.5 subvariants, as recommended by the US drug regulatory authority, will begin clinical trials this month, with the first doses also expected to begin shipping. as soon as possible in October.
“Through our initiatives around variant-matched COVID-19 vaccine candidates, we expect demand to increase in our key markets in Q4 2022, pending regulatory approval,” said Jens Holstein, CFO of BioNTech. . .
Second-quarter revenue and net income fell approximately 40% from the same period a year ago,
respectively 3,200 million euros and 1,672 million euros. BioNTech has reaffirmed its forecast for vaccine sales in 2022, that is, between 13,000 and 17,000 million euros, compared to 19,000 million last year. Its partner Pfizer forecasts $32 billion in sales of COVID-19 vaccines for the year.
Source: BFM TV
